Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3

Journal of the College of Physicians and Surgeons Pakistan

Volumn 18, Issue 10, 2008, Pages 620-624

  Farooqi, Javed Iqbal ^a,c   Farooqi, Rukhsana Javed ^b  

^a LADY READING HOSPITAL   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

^c NONE   (Pakistan)

Author keywords

Chronic hepatitis C; Conventional interferon; Genotype 2; Genotype 3; Na ve patients; Ribavirin; Sustained virological response

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 56249118034     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Hepatitis C: Global prevalence. Wkly Epidemiol Rec 1997; 72:341-44.
2. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 Suppl 1):30-34.
3. Muhammad N, Jan A. Frequency of hepatitis C in Bunner, NWFP. J Coll Physicians Surg Pak 2005; 15:11-4.
4. Mashud I, Khan H, Khattak AM. Relative frequency of hepatitis B and C viruses in patients with hepatic cirrhosis at DHQ Teaching Hospital, DI Khan. J Ayub Med Coll 2004; 16:32-4.
5. Khan TS, Rizvi F. Hepatitis B seropositivity among chronic liver disease patients in Hazara Division, Pakistan. J Ayub Med Coll 2003; 15:54-5.
6. Khan TS, Rizvi F, Rashid A. Hepatitis C seropositivity among chronic liver disease patients in Hazara, Pakistan. J Ayub Med Coll 2003; 15:53-5.
7. Farooqi JI, Farooqi RJ. Relative frequency of hepatitis B virus and hepatitis C virus infections in patients of cirrhosis in NWFP. J Coll Physicians Surg Pak 2000; 10:217-9.
8. Iqbal S, Ruknuddin. Liver cirrhosis in North-West Frontier Province of Pakistan. J Coll Physicians Surg Pak 2002; 12:289-91.
9. Ahmed F, Shah SH, Tariq M, Khan JA. Prevalence of hepatitis B carrier and HIV in healthy blood donors at Ayub Teaching Hospital, Pakistan. J Med Res 2000; 39:91-2.
10. Zaidi A, Tariq WZ, Haider KA, Ali L, Sattar A, Faqeer F, et al. Seroprevalence of hepatitis B, C and HIV in healthy blood donors in North-west of Pakistan. Pak J Pathol 2004; 15:11-6.
11. Ahmad J, Taj AS, Rahim A, Shah A, Rehman M. Frequency of hepatitis B and hepatitis C in healthy blood donors of NWFP: a single center experience. J Postgrad Med Inst 2004; 18:343-52.
12. Farooqi JI, Farooqi RJ. Relative frequency of hepatitis B virus and hepatitis C virus infections in patients of cirrhosis. J Postgrad Med Inst 2000; 14:64-7.
13. Farooqi JI, Khan PM. Prevalence of hepatitis B virus and hepatitis C virus infections in patients of cirrhosis in Swat. Pak J Gastroenterol 2002; 15:55-62.
14. Farooqi JI, Farooqi RJ. Relative frequency of hepatitis B and C virus infections in cases of hepatocellular carcinoma in North-West Frontier Province, Pakistan. J Coll Physicians Surg Pak 2000; 10:128-30.
15. Strader DB, Wright T, Thomas DI, Seef LB. AASLD Practice Guidelines: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
16. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or Peginterferon alpha-2a. Gastroenterology 2001; 120:1438-47.
17. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35.
18. Mangia A, Santoro S, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17.
19. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-65.
20. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis of outcome of antiviral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 11.
21. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 2006; 66: 1807-15.
22. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias, J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-9.
23. Neumann AV, Zeuzem S, Ferrari C. DITTO-HCV early viral kinetics report: novel decline patterns in gen 1 but not gen 2-3 patients treated with Peg-IFN-alfa-2a and ribavirin. J Hepatol 2002; 36:121.
24. Andriulli A, Dalgard O, Bjoro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38:741-8.